REFLECTION: A Clinical Practice Learning Program for Galleri®

Launched by GRAIL, INC. · Jan 12, 2022

Keywords

ClinConnect Summary

The REFLECTION trial is studying the Galleri® test, a blood test designed to help detect multiple types of cancer at an early stage. This trial aims to gather information about how the Galleri® test performs in real-life clinical settings by enrolling around 17,000 participants who have chosen to receive this test. By doing so, researchers hope to better understand how effective this test is for early cancer detection.

To participate in this study, individuals need to be at least 22 years old and willing to provide informed consent, which means they understand and agree to take part in the trial. There are no specific medical conditions that would exclude someone from joining. Participants can expect to have their blood tested using Galleri® and will be asked to complete some questionnaires. This study is currently recruiting participants, and everyone, regardless of gender, is welcome to join as long as they meet the age requirement and have been referred for the test by a healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Participants are eligible to be included in the study only if all of the following criteria apply:
• • Participant has the ability to understand and the willingness to sign a written informed consent form (ICF);
• • Participant is at least 22 years old at the time of consent;
• • A provider or their designee has ordered the Galleri® test; and
• • Participant has the ability to comprehend the participant questionnaires.
• Exclusion Criteria:
• • There are no exclusions